Gene Methylation in the Diagnosis of Barrett's Esophagus: Identification of Candidate Diagnostic Markers



Status:Completed
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - Any
Updated:8/3/2017
Start Date:May 2012
End Date:December 2016

Use our guide to learn which trials are right for you!

Utility of Aberrant Gene Methylation in the Diagnosis of Barrett's Esophagus: Identification of Candidate Diagnostic Markers

This study is to identify potential markers from esophageal biopsies and brush cytology for
feasibility of use in stool specimens for detection of Barretts Esophagus.


Inclusion Criteria:

Controls: No endoscopic evidence of Barrett's Esophagus, able to give informed consent, 18
years of age or older.

Cases: At least 1 cm of visible columnar epithelium with intestinal metaplasia on histology
confirmed by an expert GI pathologist (on biopsy), able to give informed consent, 18 years
of age or older.

Exclusion criteria:

Controls: Patients with history of esophagectomy or mucosal ablation, gastrectomy, or known
non-Barrett's esophageal pathology (e.g. eosinophilic esophagitis or achalasia), varices,
esophagitis LA Grade B, C, D will be excluded. Patients with prior history of colon polyps
or colon/esophageal/gastric/pancreatic carcinoma (unless had negative colonoscopy within 2
years to clear polyps).

Cases: Patients with history of esophagectomy or mucosal ablation, gastrectomy, or known
non-Barrett's esophageal pathology (e.g. eosinophilic esophagitis or achalasia), will be
excluded. Patients with prior history of colon polyps or colon/gastric/pancreatic carcinoma
(unless had negative colonoscopy within 2 years to clear polyps).
We found this trial at
1
site
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials